SCHEMBL1132566

SCHEMBL1132566

Oc1ccc(C=NNc2c(Cl)cc(C(F)(F)F)cc2Cl)c(O)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 11/20 0.60
KMT2A Q03164 11/20 0.60
POLB P06746 5/20 0.60
CDK5 Q00535 1/20 0.60
CDK5R1 Q15078 1/20 0.60
MAPT P10636 9/20 0.52
GAA P10253 9/20 0.52
KDM4E B2RXH2 6/20 0.52
ALDH1A1 P00352 4/20 0.52
HPGD P15428 4/20 0.52
LMNA P02545 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
PKM P14618 1/20 0.52
NPC1 O15118 4/20 0.51
L3MBTL1 Q9Y468 4/20 0.48
ALPL P05186 1/20 0.48
ALPI P09923 1/20 0.48
ALPG P10696 1/20 0.48
EIF4H Q15056 1/20 0.48
HTT P42858 5/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1132565 1.00 MEN1 (0.60) MEN1KMT2APOLBCDK5CDK5R1
SCHEMBL1133032 0.86 MEN1 (0.60) MEN1KMT2APOLBCDK5CDK5R1
SCHEMBL1132724 0.86 MEN1 (0.60) MEN1KMT2APOLBCDK5CDK5R1
SCHEMBL12506258 0.83 MAPT (0.54) MEN1KMT2APOLBCDK5CDK5R1
SCHEMBL12506257 0.83 MAPT (0.54) MEN1KMT2APOLBCDK5CDK5R1
SCHEMBL18270951 0.83 MEN1 (0.41) MEN1KMT2APOLBCDK5CDK5R1
SCHEMBL12506266 0.83 MEN1 (0.41) MEN1KMT2APOLBCDK5CDK5R1
SCHEMBL1132335 0.83 MEN1 (0.60) MEN1KMT2APOLBCDK5CDK5R1
SCHEMBL1132336 0.83 MEN1 (0.60) MEN1KMT2APOLBCDK5CDK5R1
SCHEMBL1132320 0.81 MEN1 (0.67) MEN1KMT2APOLBCDK5CDK5R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9512066-B2 Enhancers of protein degradation MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) 2016-12-06 US claimed
US-20120282629-A1 Enhancers of Protein Degradation MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) 2012-11-08 US claimed
EP-2488485-A1 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2012-08-22 EP claimed
WO-2011020883-A9 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2012-07-12 WO claimed
WO-2011020883-A1 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2011-02-24 WO claimed
EP-2287149-A1 Enhancers of protein degradation MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) 2011-02-23 EP claimed
US-9512066-B2 Enhancers of protein degradation MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) 2016-12-06 US disclosed
US-20120282629-A1 Enhancers of Protein Degradation MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) 2012-11-08 US disclosed
EP-2488485-A1 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2012-08-22 EP disclosed
WO-2011020883-A9 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2012-07-12 WO disclosed
WO-2011020883-A1 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2011-02-24 WO disclosed
EP-2287149-A1 Enhancers of protein degradation MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) 2011-02-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120282629-A1 Enhancers of Protein Degradation HTT, HYPK, TFEB MEN1 3413/4885KMT2A 2000/4885POLB 2526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.